Comparative Pharmacology
Head-to-head clinical analysis: EPITOL versus LACOSAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPITOL versus LACOSAMIDE.
EPITOL vs LACOSAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbamazepine stabilizes the inactivated state of voltage-gated sodium channels, thereby inhibiting high-frequency repetitive firing of action potentials and reducing synaptic transmission.
Selectively enhances slow inactivation of voltage-gated sodium channels, stabilizing hyperexcitable neuronal membranes and inhibiting repetitive neuronal firing.
Carbamazepine, immediate-release: initial 200 mg orally twice daily; increase by 200 mg/day at weekly intervals. Typical maintenance: 800-1200 mg/day in 2-3 divided doses. Extended-release: initial 200 mg orally twice daily; maintenance 400-600 mg twice daily.
Oral or IV: 50 mg twice daily initially; increase by 50 mg twice daily weekly to maintenance 100-200 mg twice daily. Maximum 200 mg twice daily.
None Documented
None Documented
Clinical Note
moderateLacosamide + Sulfisoxazole
"The serum concentration of Sulfisoxazole can be increased when it is combined with Lacosamide."
Clinical Note
moderateLacosamide + Fluconazole
"The serum concentration of Fluconazole can be increased when it is combined with Lacosamide."
Clinical Note
moderateLacosamide + Ketoconazole
"The serum concentration of Ketoconazole can be increased when it is combined with Lacosamide."
Clinical Note
moderateLacosamide + Delavirdine
20-40 hours (mean 30 hours); linear kinetics at therapeutic doses; decreased with concomitant enzyme-inducing drugs
Terminal elimination half-life is approximately 13 hours (range 12–16 hours) in adults. Steady state achieved after 3 days with BID dosing.
Renal: 70% (as glucuronide conjugates and other metabolites), Fecal: 30% (unchanged and metabolites)
Renal: approximately 95% (40% unchanged, remainder as O-desmethyl metabolite). Fecal: <5%.
Category C
Category C
Anticonvulsant
Anticonvulsant
"The serum concentration of Delavirdine can be increased when it is combined with Lacosamide."